The News Review:
- Nature Clinical Practice Cardiovascular Medicine Publishes Clinical…
- UQ Leads The Way n Complementary Medicine Research Australia
- Institute to transform medical records system in India
- Archemix’ ARC1779 Granted rphan Designation For The Treatment f…
- Why Glaxo Bought Sirtris
Nature Clinical Practice Cardiovascular Medicine Publishes Clinical…
Medical News Today – Medical News Today (press release) – Apr 24, 2008
A cross-sectional screening study by Jonathan Carapetis and colleagues establishes the efficacy of a screening protocol for rheumatic heart disease using portable echocardiography equipment. Elsewhere in the Clinical Research section Claudio Napoli and colleagues from II University of Naples in Italy investigate the vascular ‘niche’. Their results in mice suggest that modulating this niche could be a strategy for treating peripheral ischemia. Abel Romero-Corral and colleagues from the Mayo Clinic College of Medicine US show that high leptin levels are significantly associated with raised cardiovascular risk. “I am impressed with the high quality of the first three Clinical Research articles we have published in Nature Clinical Practice Cardiovascular Medicine” comments Editor-in-Chief Dr Valentin Fuster. “There was strong demand from the clinical cardiology community for this section and I am confident that Nature Clinical Practice Cardiovascular Medicine will become a place to publish exceptional cardiovascular research.
UQ Leads The Way n Complementary Medicine Research Australia
Medical News Today – Apr 24, 2008
” “We have got a profile in this area already and this new initiative will give UQ a very important presence as a central point for complementary medicine research” he said. In other NHMRC funding Dr Jon Adams from UQ’s School of Population Health was awarded $450771 in a Complementary and Alternative Medicine (CAM) Grant to look at CAM use among mid-age women across the urban-rural divide. Two other UQ researchers from the School of Medicine have received more than $1 million under the NHMRC’s General Practice Clinical Research Program. Associate Professor Jenny Doust received $457200 for a project to look at improving risk assessment to prevent cardiovascular disease and Associate Professor Geoff Mitchell received $561670 to look at different ways of supporting the needs of carers of patients with advanced cancer.
Institute to transform medical records system in India
CIL – Apr 24, 2008
This will help in keeping track of a patients’ medical history and generate complete records at any time. "We plan to replace the same in India as well and since some doctors are based out of USA it would be easy to monitor the progress of the patients and suggest accordingly" says Kadambi. "Presently we are in talks to open franchisee in New Delhi and Mumbai besides also open overseas centers in China and Middle East Asia” he said.
Archemix’ ARC1779 Granted rphan Designation For The Treatment f…
Medical News Today – Medical News Today (press release) – Apr 24, 2008
About The rphan Drug Act The rphan Drug Act of 1983 allows the FDA to grant orphan drug status to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200000 patients in the U. The rphan Drug Act provides the drug developer with several financial benefits and incentives related to the orphan drug including tax credits for clinical research costs ability to apply for annual grant funding clinical research trial design assistance waiver of Prescription Drug User Fee Act (PDUFA) filing fees and a seven-year period of U. marketing exclusivity if the drug is the first of its type approved for the specified indication. About TTP Thrombotic thrombocytopenic purpura or TTP is a rare blood disorder that arises from uncontrolled activation of von Willebrand Factor (vWF) a protein which under normal conditions plays a key role in maintaining the normal balance between bleeding and clotting. In patients suffering from TTP vWF binds excessively to platelets causing excessive blood clots… About The rphan Drug Act The rphan Drug Act of 1983 allows the FDA to grant orphan drug status to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200000 patients in the U. The rphan Drug Act provides the drug developer with several financial benefits and incentives related to the orphan drug including tax credits for clinical research costs ability to apply for annual grant funding clinical research trial design assistance waiver of Prescription Drug User Fee Act (PDUFA) filing fees and a seven-year period of U. marketing exclusivity if the drug is the first of its type approved for the specified indication. About TTP Thrombotic thrombocytopenic purpura or TTP is a rare blood disorder that arises from uncontrolled activation of von Willebrand Factor (vWF) a protein which under normal conditions plays a key role in maintaining the normal balance between bleeding and clotting. In patients suffering from TTP vWF binds excessively to platelets causing excessive blood clots.
Why Glaxo Bought Sirtris
Forbes – Apr 24, 2008
They have a great team. Can we bring new things to the table? f course. ne area is expertise in pre-clinical research and in formulation. Another is a long experience in small-molecule drug discovery. The whole idea is that we not swamp Sirtris. Now they can do things with a scale and know-how that’s much more difficult if you’re in a group of 60 people than if you’re in a large organization that has done this for years.
